India Pharma Market Growth At 18% In August Led By Recovery In Volumes, Non-Covid Drugs: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Driven by a volume bounce-back and recovery in sales of non-Covid-19 sales, the India Pharma Market grew 17.7% in August.
The non-Covid-19 drug range, which makes up 63% of the market, is now growing in mid-teens, while the Covid-19 portfolio still continues to grow faster.
In August, volumes aided 9% growth while price growth was 5.9%, and 2.9% from launches.
Acute therapy sales grew at a strong 24.5%, while chronic and sub-chronic therapies grew 10.1% and 14.7% respectively.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.